Churg-Strauss syndrome: Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic vasculitis of small-to medium vessels, characterized by asthma, transient pulmonary infiltrates, and hypereosinophilia.
Polyarteritis with lung involvement [Churg-Strauss]/EGPA
DOID EFO Endpoint Browser PheWeb
M13_CHURGSTRAUSS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
159 |
4. Check minimum number of eventsNone |
159 |
5. Include endpointsNone |
159 |
6. Filter based on genotype QC (FinnGen only) |
146 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Polyarteritis nodosa cum manifestationibus pulmonalibus
Similar endpoints
↥List of similar endpoints to
Polyarteritis with lung involvement [Churg-Strauss]/EGPA
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 674 | 428 | 243 |
| Only index persons | 564 | 368 | 196 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.17 | 58.51 | 60.28 |
| Only index persons | 57.40 | 56.70 | 58.70 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 146 | 96 | 50 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 54.05 | 52.68 | 56.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 152
- Matched controls
- 1520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
216.6
151
*
L04AX01
ATC
azathioprine; systemic
32.9
68.9
48
21
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
15.4
67.3
99
164
J45.1
ICD-10 Finland
Nonallergic asthma
16.0
58.0
61
61
J45.9
ICD-10 Finland
Asthma, unspecified
12.5
56.8
94
175
R03DC03
ATC
montelukast; oral
10.5
48.0
80
146
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
11.2
46.0
64
93
H02AB06
ATC
prednisolone; systemic
26.5
43.5
142
530
R03AK08
ATC
formoterol and beclometasone; inhalant
18.4
43.2
38
27
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
11.8
43.0
54
68
D72.1
ICD-10 Finland
Eosinophilia
191.6
42.2
42
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
12.9
36.4
40
41
J45.0
ICD-10 Finland
Predominantly allergic asthma
10.2
35.8
49
68
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
8.6
35.1
114
392
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.6
34.8
45
58
R03AK06
ATC
salmeterol and fluticasone; inhalant
7.8
33.1
62
123
L04AX03
ATC
methotrexate; systemic
8.2
30.0
49
83
R03AC12
ATC
salmeterol; inhalant
12.8
29.9
32
31
R03BB04
ATC
tiotropium bromide; inhalant
9.1
29.2
42
61
M05BA04
ATC
alendronic acid; oral
8.7
29.1
44
68
H02AB07
ATC
prednisone; oral
7.3
27.9
52
101
J45
ICD-10 Finland
Asthma
8.0
27.4
45
76
UDH02
NOMESCO Finland
Rhinopharyngoscopy
9.0
27.3
39
56
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.0
27.2
35
44
R01AD08
ATC
fluticasone; nasal
5.2
23.0
84
292
J33.0
ICD-10 Finland
Polyp of nasal cavity
22.1
22.0
32
18
R03BA02
ATC
budesonide; inhalant
5.2
21.7
65
191
R03BA08
ATC
ciclesonide; inhalant
6.9
21.6
39
72
R03BA05
ATC
fluticasone; inhalant
5.2
21.2
61
173
J32.4
ICD-10 Finland
Chronic pansinusitis
29.5
20.4
27
11
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.6
20.4
116
557
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.3
20.2
34
58
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.9
19.8
27
36
R03AC02
ATC
salbutamol; inhalant
6.4
19.5
127
670
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.7
19.3
27
37
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.9
18.6
28
42
J82
ICD-10 Finland
Pulmonary eosinophilia, not elsewhere classified
+∞
18.1
17
*
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
17.8
18.0
28
19
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.0
17.9
37
77
R03AK07
ATC
formoterol and budesonide; inhalant
4.4
17.7
65
219
R03AC13
ATC
formoterol; inhalant
7.8
17.7
27
41
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.9
17.4
37
79
J33.8
ICD-10 Finland
Other polyp of sinus
23.4
17.1
24
12
R03DA04
ATC
theophylline; systemic, rectal
8.4
17.1
24
33
GD1AD
NOMESCO Finland
Thorax CT examination
7.4
16.4
26
41
TDM10
NOMESCO Finland
Puncture of maxillary antrum
14.0
16.4
28
24
R50.9
ICD-10 Finland
Fever, unspecified
4.6
16.3
50
146
J45.8
ICD-10 Finland
Mixed asthma
20.1
16.2
24
14
N30.1
ICD-10 Finland
Interstitial cystitis (chronic)
43.0
15.8
19
5
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.1
15.7
65
236
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.2
15.7
59
200
Z01.8
ICD-10 Finland
Other specified special examinations
4.2
15.5
57
190
J01MA14
ATC
moxifloxacin; systemic
5.2
14.8
35
82
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
11.9
14.7
27
27
R03AC03
ATC
terbutaline; inhalant
4.7
14.4
40
107
WZC30
NOMESCO Finland
Teaching
4.2
14.4
50
159
ZX120
NOMESCO Finland
Intravenous
5.1
14.0
34
81
H02AB04
ATC
methylprednisolone; systemic
4.3
14.0
46
140
UDM02
NOMESCO Finland
Sinoscopy
28.9
13.7
18
7
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
14.0
13.6
23
19
R96
ICPC
Asthma
5.2
13.6
32
74
TGC00
NOMESCO Finland
Bronchial lavation
13.3
13.3
23
20
XG474
NOMESCO Finland
Exhalation nntrogen oxide
13.3
13.3
23
20
R03BA01
ATC
beclometasone; inhalant
4.3
13.3
43
129
M31.3
ICD-10 Finland
Wegener granulomatosis
+∞
12.7
12
*
297, ,
Kela drug reimbursment
+∞
12.7
12
*
R03DX09
ATC
mepolizumab; parenteral
+∞
12.7
12
*
3028
Kela drug reimbursment
Mepolizumab
141.2
12.6
13
*
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
11.6
11
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
11.6
11
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.7
11.4
23
46
DHB20
NOMESCO Finland
Polypectomy of internal nose
22.1
11.4
16
8
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
5.9
10.9
21
40
GX1L5
NOMESCO Finland
Exhaled nitric oxide analysis
23.6
10.9
15
7
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.5
10.8
47
171
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.9
10.8
26
61
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
64.7
10.8
12
*
KCV04
NOMESCO Finland
Distension of bladder with fluid
64.7
10.8
12
*
R01AD05
ATC
budesonide; nasal
4.9
10.6
26
62
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
10.5
10
*
A02BC01
ATC
omeprazole; systemic
3.1
10.5
64
286
J01FA06
ATC
roxithromycin; oral
3.0
10.4
85
447
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.2
10.4
57
239
R01AD01
ATC
beclometasone; nasal
3.7
10.3
40
135
XG410
NOMESCO Finland
Flow-volume spirometry
9.8
10.2
20
23
H02AB09
ATC
hydrocortisone; systemic
13.5
10.1
17
14
J46
ICD-10 Finland
Status asthmaticus
13.5
10.1
17
14
A01AB09
ATC
miconazole; local oral
4.5
10.1
27
69
N02AX02
ATC
tramadol; systemic, rectal
3.0
10.0
91
504
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.6
9.9
20
40
M05BX04
ATC
denosumab; parenteral
5.4
9.9
21
44
R06AE07
ATC
cetirizine; oral
3.0
9.9
87
473
J01MA12
ATC
levofloxacin; systemic
3.4
9.8
45
168
L04AA06
ATC
mycophenolic acid; systemic
15.0
9.4
15
11
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.7
9.3
23
55
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
9.2
30
89
M81.4
ICD-10 Finland
Drug-induced osteoporosis
39.2
9.1
11
*
R01AD09
ATC
mometasone; nasal
2.8
8.9
93
543
P01BA02
ATC
hydroxychloroquine; oral
4.6
8.9
23
57
L01AA01
ATC
cyclophosphamide; systemic
53.1
8.8
10
*
DHA10
NOMESCO Finland
Biopsy of cavity of nose
21.5
8.6
12
6
A02BC02
ATC
pantoprazole; systemic
3.6
8.6
126
877
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
4.0
8.6
27
78
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.4
8.5
16
17
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
8.4
8
*
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
7.6
8.4
19
28
D69.0
ICD-10 Finland
Allergic purpura
35.4
8.2
10
*
N06AX21
ATC
duloxetine; oral
3.4
8.1
34
119
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
5.0
7.9
18
40
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
9.7
7.7
15
17
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.4
7.7
21
54
DPA30
NOMESCO Finland
Sphenotomy
19.6
7.7
11
6
G58.7
ICD-10 Finland
Mononeuritis multiplex
84.0
7.5
8
*
B01AA03
ATC
warfarin; systemic
3.1
7.5
36
137
J47
ICD-10 Finland
Bronchiectasis
10.1
7.5
14
15
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.2
7.4
21
56
M31.0
ICD-10 Finland
Hypersensitivity angiitis
+∞
7.3
7
*
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
7.3
7
*
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
7.3
70
382
R06AX26
ATC
fexofenadine; oral
4.3
7.2
20
52
R03DC01
ATC
zafirlukast; oral
12.9
7.2
12
10
R06.0
ICD-10 Finland
Dyspnoea
2.6
7.2
57
283
R03AK11
ATC
formoterol and fluticasone; inhalant
10.8
7.2
13
13
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.4
7.1
28
94
ZXA10
NOMESCO Finland
Bilateral
2.9
7.1
41
173
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
7.0
57
287
J31.0
ICD-10 Finland
Chronic rhinitis
3.6
6.9
25
79
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.6
6.9
55
273
R01AD11
ATC
triamcinolone; nasal
3.9
6.9
22
64
J01MA02
ATC
ciprofloxacin; systemic
2.5
6.8
71
399
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
42.0
6.8
8
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
6.8
46
211
N03AX16
ATC
[U] pregabalin
2.7
6.7
46
212
ZX112
NOMESCO Finland
Subcutaneous
8.0
6.6
14
19
M13.9
ICD-10 Finland
Arthritis, unspecified
4.2
6.5
18
47
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.2
6.4
28
100
4939X
ICD-9 Finland
Asthma, unspecified[ASTHMA BRONCHIALE NUD]
19.0
6.3
9
5
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
27.9
6.3
8
*
4460B
ICD-9 Finland
Polyarteritis nodosa and allied conditions, Polyarteritis nodosa[POLYARTERITIS NODOSA CUM INFILTRATIONE PULMONUM]
+∞
6.3
6
*
L95.0
ICD-10 Finland
Livedoid vasculitis
+∞
6.3
6
*
L01BA01
ATC
methotrexate; systemic
8.2
6.3
13
17
R06AX27
ATC
desloratadine; oral
2.4
6.2
58
308
ZX100
NOMESCO Finland
Oral
13.3
6.2
10
8
H65.3
ICD-10 Finland
Chronic mucoid otitis media
10.7
6.1
11
11
UKC02
NOMESCO Finland
Cystoscopy
3.0
6.1
30
115
J40
ICD-10 Finland
Bronchitis, not specified as acute or chronic
7.8
6.1
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
37
9.05
20.69
3.1
2.4
—
—
—
0
0
24
31
9.01
17.96
1.5
1.7
—
—
—
0
0
26
15
20.61
17.67
1.6
1.0
—
—
—
0
0
135
792
7.30
17.09
25.0
10.9
4.70
4.02
e9/l
4.43
130
680
29
54
6.40
15.64
4.8
1.4
11.00
4.61
iu/ml
—
9
12
21
10
24.08
15.14
2.0
1.1
1.78
0.19
u/ml
—
15
5
113
615
4.26
14.72
3.7
2.4
81.23
78.48
nmol/l
0.49
108
553
24
41
6.76
14.01
2.7
1.9
—
—
—
0
0
60
222
3.81
13.84
2.8
1.9
—
—
—
0
0
25
49
5.91
12.71
2.2
1.5
—
—
—
0
0
29
67
5.11
12.32
4.6
3.5
2.04
1.76
mmol/l
0.19
23
52
114
674
3.77
12.01
10.0
7.3
1.22
1.21
mmol/l
0.51
98
578
23
28
9.47
11.31
1.3
1.2
—
—
—
0
0
23
29
9.14
11.09
1.6
1.7
—
—
—
0
0
21
41
5.78
10.66
2.7
1.6
—
—
—
0
0
21
42
5.64
10.39
2.7
2.0
24.06
24.56
mmol/l
0.20
21
42
103
605
3.18
10.29
7.2
4.4
34.08
36.03
g/l
2.71
97
576
42
150
3.49
9.85
2.4
1.7
—
—
—
0
0
44
164
3.37
9.63
2.3
1.6
—
—
—
0
0
88
492
2.87
9.29
7.6
3.1
—
—
—
0
0
115
746
3.22
9.16
8.0
3.6
0.00
0.00
estimate
-0.00
40
134
113
731
3.13
8.94
7.8
3.6
0.00
0.00
estimate
-0.00
40
139
20
29
7.77
8.90
7.5
7.9
—
139.80
iu/ml
—
0
5
113
733
3.11
8.85
8.1
3.6
36.76
0.00
estimate
0.49
41
147
33
115
3.39
7.93
3.2
1.3
—
—
—
0
0
17
23
8.18
7.93
1.6
1.7
—
—
—
0
0
13
11
12.79
7.74
1.5
1.6
—
—
—
0
0
18
28
7.14
7.69
1.6
1.8
—
—
—
0
0
62
313
2.66
7.64
1.9
1.6
1.23
1.26
mg/l
0.03
53
253
22
60
4.12
7.50
1.6
1.3
—
—
—
0
0
17
38
4.91
7.38
1.2
1.2
—
—
—
0
0
70
385
2.52
7.12
7.3
3.0
0.39
0.51
e6/l
0.30
60
272
16
25
7.02
6.85
3.6
2.1
16.91
15.97
%
0.44
16
25
17
29
6.46
6.84
3.0
2.1
—
—
—
0
0
16
26
6.75
6.68
3.3
1.5
8.32
8.43
kpa
0.09
16
26
29
105
3.18
6.50
3.9
3.9
82.83
81.22
ng/l
0.04
29
94
16
39
4.47
6.26
3.6
3.1
2.33
3.03
ratio
—
7
20
11
11
10.67
6.14
1.3
1.2
—
—
—
0
0
75
448
2.33
6.12
7.1
4.2
10.27
7.56
mg/mmol
0.23
53
269
68
390
2.35
6.09
8.3
3.7
0.00
0.01
estimate
0.50
39
139
84
529
2.31
6.02
7.1
3.8
33.68
29.46
ng/l
0.17
71
352
27
98
3.13
6.01
2.3
1.6
—
—
—
0
0
17
45
4.13
6.00
3.5
3.4
42.28
30.60
mg/l
0.39
12
39
14
24
6.31
5.68
1.7
1.1
—
—
—
0
0
52
275
2.35
5.52
1.4
1.3
56.06
37.24
iu/ml
0.34
18
94
15
30
5.43
5.42
1.3
1.3
—
—
—
0
0
12
19
6.75
5.19
1.8
1.5
—
—
—
0
0
21
73
3.18
5.00
2.0
1.5
—
—
—
0
0
67
408
2.15
4.96
8.0
2.8
0.00
0.00
estimate
-0.00
34
110
8
7
11.97
4.84
1.3
2.9
—
—
—
0
0
10
14
7.56
4.73
1.2
1.1
—
—
—
0
0
10
14
7.56
4.73
1.2
1.1
—
—
—
0
0
7
5
14.57
4.62
1.4
2.8
552.71
1241.00
u/ml
—
7
5
8
8
10.47
4.57
1.0
1.0
—
—
—
0
0
8
8
10.47
4.57
1.7
1.6
—
—
—
0
0
10
15
7.05
4.55
2.5
3.1
—
—
—
0
0
14
33
4.56
4.45
2.1
1.5
—
—
—
0
0
9
12
7.89
4.42
1.7
1.2
—
—
—
0
0
48
267
2.17
4.39
1.9
3.1
2.46
2.45
mmol/l
0.39
43
238
10
16
6.60
4.37
1.7
1.0
—
—
—
0
0
13
29
4.80
4.36
4.8
2.7
4.93
5.00
kpa
0.08
13
29
8
9
9.30
4.33
1.1
1.0
—
—
—
0
0
7
6
12.14
4.32
1.9
1.5
—
—
—
0
0
7
7
10.40
4.05
1.9
1.6
—
—
—
0
0
8
11
7.60
3.91
1.0
1.0
—
—
—
0
0
40
216
2.16
3.90
5.3
3.0
4.46
2.88
e6/l
0.47
21
100
79
545
1.94
3.89
8.1
3.4
0.00
0.03
estimate
0.50
33
119
9
15
6.30
3.87
4.0
2.7
—
—
—
0
0
45
256
2.08
3.83
1.5
1.3
0.96
15.16
u/ml
2.20
14
97
9
16
5.90
3.72
4.0
2.6
—
—
—
0
0
42
237
2.07
3.63
5.3
2.9
1.11
1.20
e6/l
0.04
24
121
58
369
1.92
3.57
2.7
2.7
332.00
342.39
umol/l
0.28
52
330
8
13
6.43
3.55
1.0
1.0
—
—
—
0
0
6
6
10.34
3.53
5.2
2.3
—
—
—
0
0
6
6
10.34
3.53
2.5
2.7
8.67
15.00
%
—
6
6
6
6
10.34
3.53
1.0
1.0
502.33
194.45
u/l
—
6
6
6
6
10.34
3.53
5.2
2.3
—
—
—
0
0
6
6
10.34
3.53
1.0
1.2
—
—
—
0
0
6
6
10.34
3.53
5.2
2.3
—
—
—
0
0
12
32
3.98
3.48
1.4
2.0
—
—
—
0
0
7
10
7.27
3.40
4.6
1.8
—
—
—
0
0
7
10
7.27
3.40
4.6
1.8
—
—
—
0
0
7
10
7.27
3.40
4.6
1.8
—
—
—
0
0
7
10
7.27
3.40
4.6
1.8
—
—
—
0
0
10
23
4.58
3.37
1.4
1.3
—
—
—
0
0
7
11
6.61
3.22
1.9
2.7
—
—
—
0
0
12
35
3.63
3.19
3.0
1.5
—
—
—
0
0
8
16
5.21
3.09
4.1
1.9
—
—
—
0
0
8
16
5.21
3.09
4.1
1.9
—
—
—
0
0
8
16
5.21
3.09
4.1
1.9
—
—
—
0
0
11
31
3.74
3.06
5.9
2.1
7.15
7.69
pmol/l
0.09
11
31
7
12
6.05
3.05
1.9
1.5
—
—
—
0
0
10
26
4.04
3.04
1.4
1.3
—
—
—
0
0
5
5
10.28
3.00
1.2
1.8
—
—
—
0
0
5
5
10.28
3.00
1.4
1.2
—
—
—
0
0
19
84
2.44
2.91
4.8
8.2
24.55
24.87
mmol/l
0.12
19
84
124
1044
2.02
2.88
5.8
4.7
15.21
14.71
pmol/l
1.35
119
963
6
10
6.19
2.72
1.0
1.0
—
—
—
0
0
26
138
2.07
2.61
6.3
3.6
—
—
—
0
0
42
266
1.80
2.52
4.7
4.0
114.17
199.89
ng/l
0.31
32
205
8
21
3.96
2.50
1.9
1.7
—
—
—
0
0
83
641
1.65
2.38
3.5
2.6
—
—
estimate
—
0
0
13
53
2.59
2.35
3.8
2.0
—
—
—
0
0
6
13
4.76
2.29
1.3
1.1
—
—
—
0
0
6
14
4.41
2.17
1.0
1.1
—
—
—
0
0
48
330
1.66
2.12
2.8
2.3
—
—
—
0
0
26
149
1.90
2.11
4.2
8.2
1.29
1.08
mmol/l
0.11
26
125
5
10
5.13
2.08
1.0
2.0
14.68
16.51
ug/l
—
5
10
26
150
1.88
2.07
4.3
8.0
5.00
5.19
kpa
0.57
26
142
6
15
4.12
2.06
1.5
1.1
—
—
—
0
0
6
15
4.12
2.06
1.0
1.2
—
—
—
0
0
10
38
2.74
2.04
1.1
1.1
—
3.02
—
0
6
5
11
4.66
1.95
1.6
1.1
—
—
—
0
0
6
16
3.86
1.95
1.5
1.3
—
—
—
0
0
75
589
1.54
1.85
2.7
2.1
88.94
95.76
pmol/l
0.80
45
291
37
246
1.67
1.84
1.6
1.5
—
—
—
0
0
28
177
1.71
1.67
5.6
7.4
102.57
104.15
mmol/l
1.05
28
177
145
1362
2.40
1.67
34.0
18.0
3.88
3.96
mmol/l
3.31
145
1335
14
70
2.10
1.65
5.5
3.3
24.01
24.52
mmol/l
0.32
14
70
10
43
2.42
1.62
1.8
1.3
—
—
—
0
0
7
26
2.77
1.60
2.1
1.4
—
—
—
0
0
7
26
2.77
1.60
2.1
1.4
—
—
—
0
0
13
65
2.09
1.54
5.7
3.8
51.02
49.21
%
0.09
13
65
5
15
3.41
1.53
4.8
1.8
—
—
—
0
0
15
80
1.97
1.51
3.7
4.1
96.93
186.02
ng/l
1.15
15
73
9
37
2.52
1.50
1.3
1.3
—
—
—
0
0
139
1287
1.94
1.48
7.9
6.4
39.84
39.21
mmol/mol
0.39
133
1215
5
16
3.19
1.45
4.8
1.8
—
—
—
0
0
5
16
3.19
1.45
4.8
1.8
—
—
—
0
0
5
16
3.19
1.45
4.8
1.8
—
—
—
0
0
5
16
3.19
1.45
1.8
1.0
—
—
—
0
0
5
16
3.19
1.45
4.8
1.8
—
—
—
0
0
5
16
3.19
1.45
4.8
1.8
—
—
—
0
0
98
840
1.47
1.44
3.9
3.1
—
—
—
0
0
13
67
2.03
1.43
3.5
2.4
0.76
0.62
%
0.61
13
67
135
1245
1.75
1.37
7.0
5.6
1.90
1.92
mu/l
0.06
129
1155
144
1360
2.12
1.34
33.7
17.9
139.67
139.82
mmol/l
0.31
144
1336
13
69
1.97
1.33
3.4
2.4
1.25
1.42
%
0.21
13
69
6
25
2.46
1.25
2.0
1.4
—
—
—
0
0
40
302
1.44
1.12
7.3
3.7
1.02
1.02
kg/l
0.32
30
204
7
32
2.24
1.09
2.6
1.3
—
—
—
0
0
30
217
1.48
1.04
1.7
1.6
1092.06
1202.57
nmol/l
0.27
25
175
9
49
1.89
1.00
1.9
1.8
—
—
—
0
0
14
85
1.71
0.98
1.2
1.3
31.81
113.72
u/ml
—
7
33
13
81
1.66
0.84
9.1
7.4
25.54
25.01
mmol/l
0.30
13
75
121
1123
1.38
0.83
43.8
19.2
14.10
13.60
%
4.91
121
1115
8
48
1.70
0.80
2.0
1.2
—
—
—
0
0
0
24
0.00
0.80
0.0
1.2
—
6.21
—
0
24
146
1411
1.88
0.75
44.3
20.1
79.95
75.28
umol/l
1.16
146
1395
9
58
1.59
0.71
1.3
1.4
41.60
23.22
iu/l
—
9
46
5
27
1.88
0.69
1.2
1.1
—
—
—
0
0
0
20
0.00
0.61
0.0
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
2.35
—
0
13
16
115
1.44
0.59
2.6
2.9
54.80
67.43
ml/min/173m2
—
10
46
68
608
1.21
0.53
2.1
1.9
1.39
1.37
mmol/l
0.07
59
508
101
939
1.23
0.53
4.4
3.3
67.62
51.73
u/l
0.60
96
892
9
65
1.41
0.51
1.1
1.0
—
—
—
0
0
24
296
0.78
0.49
5.0
4.6
18.51
22.59
%
0.76
13
125
7
49
1.45
0.46
2.0
1.4
—
—
—
0
0
39
341
1.19
0.37
1.3
1.2
0.54
1.94
u/ml
—
5
99
28
239
1.21
0.34
1.8
1.5
—
—
—
0
0
6
45
1.35
0.34
1.7
1.1
—
—
—
0
0
6
46
1.32
0.33
1.7
1.1
—
—
—
0
0
43
388
1.15
0.29
2.4
1.7
17.75
22.25
nmol/l
1.75
38
323
11
139
0.78
0.28
10.5
8.1
—
—
—
0
0
8
64
1.26
0.28
1.6
1.7
—
—
—
0
0
9
74
1.23
0.26
1.4
1.3
—
—
—
0
0
19
222
0.84
0.25
2.7
3.0
0.93
0.74
ug/l
0.64
13
137
12
146
0.81
0.23
1.6
2.2
3.47
3.22
ratio
—
7
122
14
116
1.23
0.23
2.3
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
189.45
—
0
12
0
13
0.00
0.21
0.0
1.4
—
60.72
—
0
13
15
127
1.20
0.20
2.5
1.9
—
—
—
0
0
8
69
1.17
0.17
4.1
7.6
14.24
15.94
%
—
8
64
146
1443
1.30
0.16
55.1
23.9
133.90
135.57
g/l
0.78
146
1431
146
1442
1.32
0.16
54.5
23.7
91.40
91.36
fl
0.03
146
1430
146
1442
1.32
0.16
54.5
23.7
4.47
4.49
e12/l
0.20
146
1417
146
1442
1.32
0.16
54.7
24.1
40.76
40.61
%
0.18
146
1429
146
1440
1.35
0.16
54.7
23.8
277.91
250.22
e9/l
4.53
146
1421
5
44
1.14
0.10
2.2
1.4
—
255.94
miu/ml
—
0
17
15
165
0.90
0.09
5.6
4.6
33.80
33.02
%
0.11
15
106
6
54
1.12
0.09
1.5
1.6
—
—
—
0
0
132
1313
1.04
0.01
6.8
5.1
5.96
5.96
mmol/l
0.00
127
1226
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
65.40
—
0
5
0
9
0.00
-0.00
0.0
3.6
—
10.43
—
0
9
27
270
1.00
-0.00
1.6
1.7
415.68
472.65
pmol/l
0.86
22
232
0
9
0.00
-0.00
0.0
3.6
—
4.67
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint M13_CHURGSTRAUSS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_CHURGSTRAUSS | 1.776 [1.31, 2.4] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.509 |
During the follow-up period (1.1.1998 — 31.12.2019), 95 out of 338 females with M13_CHURGSTRAUSS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_CHURGSTRAUSS | 1.771 [1.23, 2.56] | 0.002 |
| Birth year | 0.988 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 192 males with M13_CHURGSTRAUSS died.
Mortality risk
Mortality risk for people of age
years, who have M13_CHURGSTRAUSS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.195% | 0.339% |
| 5 | 1.128% | 2.094% |
| 10 | 2.675% | 5.255% |
| 15 | 5.195% | 9.979% |
| 20 | 9.422% | 16.502% |
Relationships between endpoints
↥Index endpoint: M13_CHURGSTRAUSS – Polyarteritis with lung involvement [Churg-Strauss]/EGPA
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data